Help | Scores |Exit
Fragmin | Magnex | Solu Medrol
Nadroparin Drug Name:  
A|B|C|D|E|F|G|H|I|K|L|M|N|O|P|Q|R|S|T|V|Z
Indications
Dosages
Interactions
Precautions
Contraindications
Adverse Reactions
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interactions:

Acenocoumarol

  • Adverse Effect Increased risk of bleeding and hematoma when neuraxial anesthesia is employed
  • Clinical Management Acenocoumarol should be discontinued prior to the initiation of therapy with Nadroparin . If this is not possible, patients receiving Nadroparin and Acenocoumarol concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy.

    Celecoxib

  • Adverse Effect an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed
  • Clinical Management Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.

    Dipyridamole

  • Adverse Effect Increased risk of bleeding and hematoma when neuraxial anesthesia is employed
  • Clinical Management Drugs which affect hemostasis should be discontinued prior to the initiation of therapy with Nadroparin or heparinoid. If this is not possible, patients receiving Nadroparin or heparinoid and Dipyridamole concurrently should be monitored closely for bleeding, which may be serious.

    Flurbiprofen

  • Adverse Effect an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed
  • Clinical Management Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.

    Ibuprofen

  • Adverse Effect an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed
  • Clinical Management Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.

    Indomethacin

  • Adverse Effect an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed
  • Clinical Management Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.

    Ketoprofen

  • Adverse Effect an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed
  • Clinical Management Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.

    Ketorolac

  • Adverse Effect an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed
  • Clinical Management Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.

    Mefenamic Acid

  • Adverse Effect an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed
  • Clinical Management Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.

    Meloxicam

  • Adverse Effect an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed
  • Clinical Management Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.

    Nabumetone

  • Adverse Effect an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed
  • Clinical Management Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.

    Naproxen

  • Adverse Effect an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed
  • Clinical Management Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.

    Nimesulide

  • Adverse Effect an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed
  • Clinical Management Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.

    Oxyphenbutazone

  • Adverse Effect an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed
  • Clinical Management Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.

    Paracetamol

  • Adverse Effect an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed
  • Clinical Management Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.

    Phenacetin

  • Adverse Effect an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed
  • Clinical Management Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.

    Phenindione

  • Adverse Effect Increased risk of bleeding and hematoma when neuraxial anesthesia is employed
  • Clinical Management Phenindione should be discontinued prior to the initiation of therapy with Nadroparin . If this is not possible, patients receiving Nadroparin and Phenindione concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy.

    Phenylbutazone

  • Adverse Effect an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed
  • Clinical Management Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.

    Piroxicam

  • Adverse Effect an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed
  • Clinical Management Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.

    Tenoxicam

  • Adverse Effect an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed
  • Clinical Management Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.

    Warfarin

  • Adverse Effect Increased risk of bleeding and hematoma when neuraxial anesthesia is employed
  • Clinical Management Warfarin should be discontinued prior to the initiation of therapy with Nadroparin . If this is not possible, patients receiving Nadroparin and Warfarin concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy.
  • Naloxone Hydrochloride
    Naproxen
    Neomycin Sulfate
    Neostigmine Bromide
    Niacin(nicotinic acid)
    Nifedipine
    Nitrofurantoin
    Nitroprusside Sodium
    Norepinephrine Bitartrate
    Nortriptyline Hydrochloride
    Nystatin
    Nitrofurazone
    Nitroxazapine
    Netilmicin
    Noradrenaline
    Nevirapine
    Nicergoline
    Niclosamide
    Noradrenaline - resp
    Nicorandil
    Norethindrone
    Nicotine
    Norethisterone
    Nicotinic Acid
    Norfloxacin - Ocular
    Nortriptyline
    Norfloxacin
    Nafarelin
    Nimesulide
    Nylidrin
    Nalidixic Acid
    Nystatin - VU
    Naltrexone
    Nandrolone
    Nitrendipine
    Nitrazepam
    Nimodipine
    Naphazoline
    N-acetylcysteine
    Natamycin - Ocular
    Natamycin - VU
    Nateglinide
    Nabumetone
    Nefopam
    Nadroparin
     
    Disclaimer